Advertisement
Advertisement
RPRX
Royalty Pharma plc Class A Ordinary Shares
67.41
USDSponsored
+0.11
+0.16%
Nov 09, 09:41 UTC -5
Open
Royalty Pharma plc Class A Ordinary Shares (RPRX) Earnings
RPRX Earnings Reports
Positive Surprise Ratio
RPRX beat 16 of 26 last estimates.
62%
Next Report
Date of Next Report
Feb 09, 2027
Estimate for Q4 26 (Revenue/ EPS)
$837.55M
/$1.57
Implied change from Q3 26 (Revenue/ EPS)
+21.37%
/+29.75%
Implied change from Q4 25 (Revenue/ EPS)
+34.66%
/+6.80%
Royalty Pharma plc Class A Ordinary Shares earnings per share and revenue
On Nov 04, 2026, RPRX reported earnings of 1.21 USD per share (EPS) for Q3 26, beating the estimate of 1.20 USD, resulting in a 0.39% surprise. Revenue reached 690.10 million, compared to an expected 812.46 million, with a -15.06% difference. The market reacted with a +1.75% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 1.57 USD, with revenue projected to reach 837.55 million USD, implying an increase of 29.75% EPS, and increase of 21.37% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
TG Therapeutics, Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.37
Actual
$0.35
Surprise
-6.44%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$3.85
Actual
-$3.23
Surprise
+16.12%
Immunovant, Inc. Common Stock
Report Date
Nov 09, 2026 For Q2 27
Estimate
-$0.74
Actual
-$0.47
Surprise
+37.07%
Bicara Therapeutics Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.84
Actual
-$1.04
Surprise
-23.02%
Kamada Ltd
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.13
Actual
$0.14
Surprise
+7.61%
Editas Medicine, Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.19
Actual
-$0.15
Surprise
+22.04%
Compugen Ltd
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Spruce Biosciences, Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$5.78
Actual
-$8.51
Surprise
-47.00%
Mereo BioPharma Group plc - ADR
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.01
Actual
-$0.01
Surprise
+1.96%
CervoMed Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.39
Surprise
+21.97%
FAQ
What were Royalty Pharma plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Royalty Pharma plc Class A Ordinary Shares reported EPS of $1.21, missing estimates by 0.39%, and revenue of $690.10M, -15.06% below expectations.
How did the market react to Royalty Pharma plc Class A Ordinary Shares's Q3 2026 earnings?
The stock price moved up 1.75%, changed from $66.40 before the earnings release to $67.56 the day after.
When is Royalty Pharma plc Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Feb 09, 2027.
What are the forecasts for Royalty Pharma plc Class A Ordinary Shares's next earnings report?
Based on --
analysts, Royalty Pharma plc Class A Ordinary Shares is expected to report EPS of $1.57 and revenue of $837.55M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.